NLRP3 and acute kidney injury: Liao’s research (Liao et al., 2021) highlighted that nodakenin markedly inhibited I/R-induced AKI in mice and hypoxia-treated primary RTECs by modulating the activation of the NF-κB and ROS-induced NLRP3 inflammasome, thereby improving inflammation in I/R-AKI.